BioWorld

July 23, 2003

Roche Licenses Rights To IL-15 Preclinical Program From Cardion

Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today) Read More

House Passes BioShield Bill That Excludes Two Industry Incentives

Vancomycin Can't Buck All Bugs; Hospitals Call All Hands To Curb Patient Infection, Test New Drug

Symyx Signs ExxonMobil Deal: $200M For Fuel-Products Work

Onyx Raises $71M In Public Offering Of 5 Million Shares

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

Other News To Note

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for Feb. 2, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...

Illustration of brain with neuron receptor

5-HT2R allosteric ligands attenuate cocaine use and seeking behavior

BioWorld Science

Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...